Related Experiment Video

Updated: Apr 18, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Recent advances in the HER2 targeted therapy of gastric cancer

Tasuku Matsuoka1, Masakazu Yashiro1

  • 1Tasuku Matsuoka, Masakazu Yashiro, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

World Journal of Clinical Cases
|January 23, 2015
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2)-targeted therapies improve outcomes for metastatic gastric cancer. However, resistance develops, prompting research into new combination treatments to enhance efficacy.

Area of Science:

  • Oncology
  • Molecular Targeted Therapy
  • Gastrointestinal Cancer Research

Background:

  • Molecular targeted therapies, specifically targeting human epidermal growth factor receptor 2 (HER2), represent a significant advancement in gastric cancer treatment.
  • Trastuzumab, a HER2-targeted therapy used with chemotherapy, has shown benefits in response rates, time to progression, and overall survival for metastatic HER2-positive gastric cancer patients.

Purpose of the Study:

  • To review the current clinical applications of agents targeting HER2 in gastric cancer.
  • To discuss ongoing clinical trials investigating HER2-targeted agents in combination therapies for gastric cancer.

Main Methods:

  • Literature review of clinical applications and ongoing trials of HER2-targeted agents in gastric cancer.
  • Analysis of treatment outcomes, including response rates, progression, and survival, associated with HER2-targeted therapies.

Main Results:

  • HER2-targeted therapies, such as trastuzumab, have improved outcomes in metastatic HER2-positive gastric cancer.
  • Acquired resistance to trastuzumab is a significant challenge, similar to its occurrence in breast cancer.

Conclusions:

  • Despite resistance, HER2-targeted agents remain crucial in gastric cancer therapy.
  • Ongoing research focuses on novel combination strategies, including cytotoxic agents and other monoclonal antibodies, to overcome resistance and improve treatment efficacy.
Keywords:
Gastric cancerHuman epidermal growth factor receptor 2Targeting therapyTrastuzumab

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K